NCT02584075

Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Type 2 diabetes mellitus (T2DM) is an important risk factor of cardio-cerebral vascular disease such as coronary heart disease. GLP-1 is a kind of incretin secreted by the L-cell located in Ileum. It acts as an incretin hormone by protentiating glucose-stimulated insulin release. Recent studies reported that GLP-1 RA can protect the vascular endothelial and prevent vascular from atherosclerosis. Investigators design this study to investigate exenatide's effect on the improvement of the coronary endothelial function by evaluating endothelium dependent diastolic function and testing the vascular endothelial active substance and related inflammatory factors.

Conditions

• Coronary Endothelial Function

Interventions

Type	Name	Description
DRUG	Byetta (Exenatide)	Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
DRUG	Glucophage ( Metformin Hydrochloride)	Metformin 500mg Tid

Timeline

• Start date: 2015-11-01
• Primary completion: 2017-11-01
• Completion: 2018-01-01
• First posted: 2015-10-22
• Last updated: 2015-10-22